Podocytes are the elegant, foot-shaped cells that wrap around the kidney’s glomerular capillaries. Their interlocking foot processes are joined by specialized junctions called slit diaphragms, which form the final and most size-selective layer of the blood filtration barrier. When podocytes are stressed, these foot processes retract and broaden in a change known as effacement, initially a protective adaptation that keeps the cells anchored to the glomerular basement membrane. That matters because the body has only a limited capacity to regenerate podocytes once they are lost. Understanding what triggers reversible effacement, as opposed to permanent damage, has been a central question in nephrology.

The new work focuses on TLR4, a pattern-recognition receptor long known to sit on the podocyte surface. TLR4 is the canonical sensor of lipopolysaccharide, the endotoxin shed from the outer membranes of gram-negative bacteria. Injecting LPS into mice is a standard model of sepsis, and it reliably produces proteinuria and foot process effacement within 24 hours, with the glomerular changes fully reversible after a single dose. That reversibility has fueled the provocative hypothesis that proteinuria may, in some circumstances, be a purposeful response, accelerating the clearance of potentially toxic substances from the circulation.

Studying TLR4 in living animals is notoriously messy. The receptor is abundant on monocytes, macrophages, dendritic cells, and epithelia, and its activation floods the bloodstream with inflammatory cytokines that alter hemodynamics across the whole organism. To isolate the podocyte’s own contribution, the team turned to immortalized MPC-5 mouse podocytes, differentiated into a mature phenotype that robustly expresses nephrin and podocin. The cells were grown as confluent monolayers on transwell inserts, where they form nephrin-dependent barriers whose selectivity closely mirrors the living glomerular filter. This reductionist design ensured that every response observed was initiated by TLR4 receptors on podocytes themselves, with no other cell type present.

To activate the receptor cleanly, the researchers used CRX527, a synthetic aminoalkyl glucosaminide 4-phosphate that structurally mimics lipid A, the toxic core of LPS, and acts as a highly selective TLR4 agonist. Its effects were confirmed as TLR4-specific because they were completely abolished by TAK242, a structurally unrelated antagonist that binds only TLR4. At a concentration of 0.7 micromolar, within the middle of the known dose-response range, CRX527 exposures of just one hour significantly increased the flux of fluorescently labeled albumin across the podocyte monolayer. Remarkably, after a 72-hour recovery period in normal media, that permeability increase disappeared entirely, demonstrating that the acute leak is fully reversible.

The researchers then traced which intracellular messages carried that rapid signal. A brief exposure to CRX527 provoked a fast burst of Erk MAP kinase activation, detectable as phosphorylation of Erk1/2 within 30 minutes, followed by a rise in cytosolic reactive oxygen species that persisted through 24 hours of agonist exposure. Pharmacological dissection showed that the one-hour permeability increase was blunted by TEMPOL, a membrane-permeable ROS quencher, and by PD98059, a MEK1 inhibitor that blocks the Erk pathway. In contrast, the permeability effect persisted when NFκB signaling was blocked with JSH-23, consistent with the observation that one hour of agonist exposure is simply not enough to activate the transcription factor at all.

A second response required longer stimulation. After 24 hours of continuous CRX527 exposure, the culture medium accumulated markedly elevated levels of soluble nephrin, measured by ELISA, indicating that the ectodomains of this slit diaphragm protein had been proteolytically cleaved from the cell surface. The shedding was blocked by the broad-spectrum metalloproteinase inhibitor Batimastat, implicating matrix metalloproteinases or related sheddase enzymes in the ADAM family. Critically, one hour of exposure, enough to open the permeability barrier, produced no shedding at all, and the shedding response required Erk activation but, unlike the permeability change, did not depend on ROS and persisted despite NFκB blockade. It also required ongoing protein synthesis, being abolished by cycloheximide.

Importantly, the shedding was not a byproduct of cells dying or detaching. Immunoblot analysis showed that total cellular abundance of nephrin, podocin, and synaptopodin, the core structural proteins of foot processes, was unchanged after 24 hours of CRX527 treatment, which would not be expected if cells had sloughed off the substrate. The team also ruled out TRPC6 calcium channels as essential mediators, since nephrin shedding continued in the presence of SAR7334, a selective TRPC6 inhibitor, even though sustained TRPC6 activation is known to produce similar shedding. One intriguing casualty of prolonged stimulation was WT-1, a transcription factor that maintains the mature podocyte phenotype, which declined significantly after 24 hours, hinting at early dedifferentiation.

The darkest consequence emerged only with the most sustained activation. Seventy-two hours of continuous CRX527 exposure drove a marked increase in cleaved caspase-3, the executioner enzyme of apoptosis, confirmed independently by Annexin V measurement. This cell death program was blocked by TAK242, and pharmacological mapping showed it required both ROS generation and NFκB activation, while remaining insensitive to Erk inhibition. Twenty-four hours, by contrast, was not sufficient to cleave caspase-3. The researchers also connected the pathway through MyD88, the canonical adapter linking TLR4 to downstream transducers, since siRNA knockdown of MyD88 suppressed NFκB activation.

The overall picture is one of a single receptor encoding time: minutes of TLR4 activity transiently loosen the filtration barrier through ROS and Erk, a day of activity strips nephrin from the junction through metalloprotease-dependent shedding, and days of unremitting signaling kill the cell through a ROS- and NFκB-dependent apoptotic route. The findings support the idea that at least part of the proteinuria seen after endotoxin exposure in animals stems from direct podocyte effects rather than systemic inflammation. They also provide a plausible mechanism for benign transient proteinuria after minor infections, fever, or intense exercise, and echo known parallels with angiotensin II signaling, which similarly recruits Erk to promote nephrin internalization and loosens the filter. The authors caution that the work is entirely in vitro and that agonist concentrations may exceed those generated physiologically, but the model now stands as a testable framework for a common and usually harmless clinical phenomenon.

Subject of Research: TLR4 signaling pathways that drive albumin permeability, nephrin shedding, and apoptosis in cultured podocytes

Article Title: TLR4 signaling cascades leading to increases in albumin permeability, nephrin ectodomain shedding, and apoptosis in MPC‐5 podocytes

Article References: Kim, E. Y., & Dryer, S. E. (2026). TLR4 signaling cascades leading to increases in albumin permeability, nephrin ectodomain shedding, and apoptosis in MPC ‐5 podocytes. Physiological Reports, 14(20), Article e71147. https://doi.org/10.14814/phy2.71147

Image Credits: AI Generated

DOI: 10.14814/phy2.71147

Keywords: TLR4, podocytes, nephrin, proteinuria, kidney filtration barrier, lipopolysaccharide, reactive oxygen species, NFκB, Erk MAP kinase, apoptosis, slit diaphragm, metalloproteinases

Podocytes are highly specialized epithelial cells wrapped around the glomerular capillaries, and their interlocking foot processes form the slit diaphragm, a structure essential to the glomerular filtration barrier. When podocytes are injured, proteins leak into the urine, producing the massive proteinuria that defines podocytopathies such as minimal change disease, focal segmental glomerulosclerosis and membranous nephropathy. Clinically, infection is the most common trigger of recurrent proteinuria in these conditions: adults with early-onset, frequently relapsing minimal change disease often develop oedema and heavy protein loss shortly after respiratory infections. Yet even when immunosuppressive and supportive therapies work initially, relapses remain frequent, and the mechanisms by which infection-associated inflammatory signals aggravate podocyte injury have remained incompletely defined.

Arachidonic acid offered a plausible suspect. This omega-6 polyunsaturated fatty acid is stored esterified in cell-membrane phospholipids, and circulating free levels are normally very low, roughly 0.1 micromoles per litre, because the molecule is rapidly bound by albumin. During infection or tissue injury, inflammatory cytokines activate membrane phospholipases that liberate free arachidonic acid, raising its circulating concentration. In kidney disease, proteinuria and hypoalbuminaemia may further reduce albumin’s binding capacity, enlarging the biologically available pool of the fatty acid. Previous work had linked arachidonic acid metabolism to renal inflammation and shown that excessive amounts can harm podocytes, but whether the lipid amplifies damage through metabolic stress in minimal change disease-related injury was unknown.

To find out, the researchers used a puromycin aminonucleoside, or PAN, model, a standard experimental mimic of minimal change disease. Male Sprague-Dawley rats received a single intraperitoneal PAN injection, and ten days later, once podocyte injury was established, half of the injured animals received an intraperitoneal dose of arachidonic acid at 3 milligrams per kilogram. The team was careful to frame this PAN-plus-AA condition as an injury-exacerbation model rather than a faithful reproduction of infection-triggered clinical relapse, since no true infectious stimulus was present. Serum measurements confirmed the design worked: arachidonic acid levels rose from about 4.5 nanograms per millilitre in controls to 8.2 in PAN-treated rats and 12.0 in the combined group, with the combined group also exceeding rats given the fatty acid alone.

The structural consequences were striking. Light microscopy showed no prominent glomerular sclerosis or fibrosis in any group, consistent with the subtle appearance of minimal change disease, so the investigators turned to transmission electron microscopy. There, the glomerular basement membrane thickened from 155 nanometres in controls to 227 nanometres after PAN and 274 nanometres after PAN plus arachidonic acid. Foot-process width swelled from 0.42 to 0.73 and then 1.00 micrometres across the same groups, while the density of foot processes per micrometre of basement membrane fell from 2.04 to 1.16 to 0.81, all differences between the PAN and combined groups statistically significant. Nephrin, the slit-diaphragm protein that anchors the filtration barrier, declined after PAN and dropped further with added arachidonic acid, as shown by both immunofluorescence and Western blotting.

The metabolic story proved equally compelling. Electron microscopy revealed severe mitochondrial injury in podocytes from the combined-treatment rats, including swelling, size heterogeneity, matrix rarefaction and fragmented or dissolved cristae, with quantified increases in mean mitochondrial area, cristae-damage rate and overall damage score. The mitochondrial outer-membrane protein TOM20 was reduced in parallel. The team then examined the PKM enzyme family: PKM1 and PKM2 signals within nephrin-positive glomerular regions both fell after PAN and fell further with arachidonic acid, while phosphorylated PKM2 at the Tyr105 residue rose. Because Tyr105 phosphorylation disrupts formation of PKM2’s active tetramer, the increase signals dysfunction rather than activation. Functionally, total pyruvate kinase activity declined, and renal pyruvate, lactate and ATP levels all dropped, reaching their lowest points in the combined group.

Cultured human podocytes reproduced the pattern. Differentiated cells exposed to PAN alone showed disrupted F-actin stress fibres and reduced nephrin; adding arachidonic acid produced the lowest F-actin intensity and the greatest nephrin loss. The same metabolic signature emerged: reduced PKM1 and PKM2 abundance, elevated phospho-PKM2, diminished pyruvate kinase activity, and lower lactate, pyruvate and ATP. Mitochondria fared worse with the combination, showing greater swelling and cristae damage, a reduced JC-1 aggregate-to-monomer ratio indicating loss of membrane potential, decreased TOM20, and elevated mitochondrial reactive oxygen species detected by MitoSOX staining. Downstream, TUNEL assays revealed more apoptotic cells, and DCFH-DA staining plus flow cytometry confirmed heightened intracellular oxidative stress in the combined-treatment group.

The rescue experiment provided the study’s most translational moment. TEPP-46, a selective PKM2 activator that stabilizes the enzyme’s active tetrameric state, was applied to podocytes under PAN-plus-arachidonic-acid conditions. Treatment restored a more organized actin cytoskeleton, reduced apoptosis, increased PKM2 expression while lowering phospho-PKM2, and raised pyruvate kinase activity along with lactate, pyruvate and ATP production. Mitochondrial readouts improved as well: TOM20 abundance rose, electron microscopy showed less swelling and cristae damage, MitoTracker and JC-1 signals indicated better mitochondrial mass and membrane potential, and ROS levels fell. Together these results indicate that PKM2 activation can partially reverse the metabolic and mitochondrial collapse that arachidonic acid imposes on injured podocytes.

The authors frame their findings within a two-axis model of arachidonic acid toxicity. Their earlier work showed that the fatty acid activates a PKA-c-Abl-nephrin pathway driving actin cytoskeletal remodelling; the present study adds a PKM2-associated metabolic axis that impairs energy production and mitochondrial homeostasis. The two pathways may converge, since actin remodelling demands ATP and mitochondrial ROS can destabilize nephrin and the cytoskeleton, though the data do not establish a strict sequence. Limitations are acknowledged: the model lacks a true infectious trigger, lipidomic analysis did not distinguish free from esterified arachidonic acid or eicosanoid products such as those from COX2/PGE2 signalling, glycolytic flux and respiration were not directly measured by ECAR or OCR assays, and the TEPP-46 rescue was performed only in vitro. Notably, omega-3 fatty acids have recently been reported to protect the podocyte and kidney, underscoring the divergent effects of different polyunsaturated fat subclasses. Even so, the study supports further testing of PKM2-targeted metabolic intervention, including in vivo rescue studies and models that better recapitulate infection-associated relapse, offering hope that a metabolic lever might one day help prevent the proteinuric crashes that follow infections in vulnerable patients.

Subject of Research: Arachidonic acid exacerbation of puromycin aminonucleoside-induced podocyte injury through PKM2-linked glycolytic and mitochondrial dysfunction

Article Title: Arachidonic Acid Disrupts PKM2‐Linked Glycolysis‐Related Metabolism and Exacerbates PAN‐Induced Podocyte Injury

Article References: Nie, K., Gao, X., Liu, M., You, D., Weng, M., Zheng, T., Lin, J., Rao, S., Zhuo, Y., Wan, J., & Yang, L. (2026). Arachidonic Acid Disrupts PKM2 ‐Linked Glycolysis‐Related Metabolism and Exacerbates PAN ‐Induced Podocyte Injury. Journal of Cellular and Molecular Medicine, 30(19), Article e71404. https://doi.org/10.1111/jcmm.71404

Image Credits: AI Generated

DOI: 10.1111/jcmm.71404

Keywords: arachidonic acid, podocytes, PKM2, glycolysis, minimal change disease, mitochondrial dysfunction, puromycin aminonucleoside, nephrin, oxidative stress, TEPP-46, kidney disease, proteinuria

Fibrillary glomerulonephritis, first described in 1977, is characterized by the accumulation of non-amyloid fibrils, predominantly within the glomeruli, the microscopic filtering units of the kidney. Each glomerulus contains a sophisticated filtration barrier composed of fenestrated endothelial cells, the glomerular basement membrane, and podocytes, highly specialized epithelial cells whose interdigitating foot processes are joined by slit diaphragms built from proteins such as nephrin, podocin, and CD2-associated protein. When fibrillary deposits infiltrate the mesangium and capillary walls, this barrier is breached, and plasma proteins leak into the urine. The result is typically nephrotic-range proteinuria, microscopic hematuria, hypertension, and progressive loss of kidney function.

The patient arrived at the Department of Nephrology at Charles University and General University Hospital in Prague with bilateral leg swelling, blood in her urine, and an unintentional weight loss of 15 kilograms over two years. Her history included well-controlled hypertension, hypothyroidism, and rheumatoid arthritis diagnosed roughly five years earlier. Laboratory testing told a familiar story of glomerular injury: serum creatinine of 108 micromoles per liter, indicating mildly impaired kidney function; 24-hour urine protein excretion of 4.6 grams, well into the nephrotic range; serum albumin depressed to 30 grams per liter; and dysmorphic red blood cells in the urinary sediment, a signature of glomerular bleeding.

The kidney biopsy, performed on the fifth day of hospitalization, showed focal segmental mesangial expansion and increased mesangial cellularity, with 11 of 31 glomeruli globally sclerotic and two containing fibrocellular crescents. Interstitial fibrosis and tubular atrophy involved about a third of the renal cortex. Critically, Congo red and Saturn red stains were negative, ruling out amyloidosis, the great mimic of fibrillary disease. Immunofluorescence microscopy then revealed diffuse granular staining for IgG and complement C3 in the mesangium and along capillary walls, with moderate staining for lambda light chain and none for kappa, an apparent lambda-restricted pattern that immediately raised a diagnostic alarm.

Here the case becomes technically fascinating. Light-chain restriction on routine frozen-section immunofluorescence alone does not prove that deposits are truly monotypic. Unequal staining sensitivity or masking of immunoglobulin epitopes can produce a falsely restricted pattern, concealing a mixed population of antibodies beneath an apparently single one. To resolve the ambiguity, the team performed two additional investigations. IgG-subclass staining showed isolated IgG1 positivity, with IgG2, IgG3, and IgG4 all negative. Immunofluorescence on pronase-digested paraffin-embedded tissue, a technique that strips away masked epitopes, confirmed strong IgG and lambda staining with persistent absence of kappa. Concordant restriction to a single IgG subclass and a single light chain established a true monotypic IgG1-lambda phenotype.

Electron microscopy sealed the morphological diagnosis, revealing randomly oriented, non-branching fibrils measuring approximately 20 nanometers, accompanied by podocyte foot-process effacement, the structural correlate of heavy proteinuria. These dimensions distinguish fibrillary glomerulonephritis from immunotactoid glomerulopathy, which features larger microtubular deposits with hollow centers and more organized arrangement. Meanwhile, DNAJB9 immunohistochemistry showed strong, diffuse staining of the glomerular deposits. DNAJB9, a member of the DnaJ heat-shock protein family that functions as an endoplasmic-reticulum co-chaperone involved in protein folding, was identified through proteomic studies as an abundant component of fibrillary deposits. As a diagnostic biomarker it boasts roughly 98 percent sensitivity and over 99 percent specificity, making it indispensable for separating fibrillary glomerulonephritis from amyloidosis, immunotactoid glomerulopathy, and other organized-deposit diseases.

Monotypy carries serious clinical implications, because it raises the specter of monoclonal gammopathy of renal significance, a condition in which a hidden clone of B cells or plasma cells produces the very immunoglobulin that damages the kidney. Yet the systemic workup came back clean. Serum immunofixation detected no monoclonal protein, serum free light-chain concentrations and the kappa-to-lambda ratio were within reference ranges, hepatitis B and C were excluded serologically, and no hematological or other malignancy was identified. Bone marrow biopsy was deemed unnecessary given the absence of any circulating monoclonal protein. The authors are careful, however, to describe their findings as monotypic disease without demonstrable monoclonal gammopathy rather than claiming a clonal disorder was definitively excluded, since a small or non-secretory clone cannot be absolutely ruled out without marrow examination.

The association with rheumatoid arthritis adds another layer of rarity. In a multi-institutional cohort of 226 patients with fibrillary glomerulonephritis reported by Andeen and colleagues, only three had rheumatoid arthritis, roughly 1.3 percent, and none of 66 patients in the Mayo Clinic cohort had the disease. The mechanism linking chronic autoimmune inflammation to fibrillary glomerular injury remains uncertain. Persistent B-cell activation and dysregulated immunoglobulin production in autoimmune disorders could theoretically promote immunoglobulin-associated glomerular damage, and the presence of IgG1 and DNAJB9 within the deposits has fueled speculation that DNAJB9 may act as a putative autoantigen in an IgG-mediated autoimmune response. The authors emphasize, though, that fibrillary glomerulonephritis is not considered a conventional immune-complex complication of rheumatoid arthritis, and the coexistence should be interpreted as a rare clinicopathological association rather than proof of causation.

Treatment posed its own dilemma, since no standardized or definitively effective therapy for fibrillary glomerulonephritis exists. After discussion at a clinicopathological seminar, the team selected rituximab, a B-cell-depleting monoclonal antibody, based on limited evidence suggesting potential benefit when an immune-mediated process is suspected. The patient received one gram intravenously at baseline, a second gram two weeks later, and a third dose six months after initiation. The response was clinically meaningful: at 14 months, proteinuria had fallen from 4.6 grams to approximately 1.0 gram per 24 hours, and serum albumin had climbed from 30 to 38 grams per liter. Serum creatinine rose modestly to 133 micromoles per liter, indicating persistent kidney dysfunction without progression to kidney failure. The authors caution that this uncontrolled observation cannot establish causality or general efficacy.

The story ends somberly. The patient subsequently developed COVID-19 and died, with the infection documented as the direct cause of death, truncating follow-up at 14 months. The limitations of a single-patient report, incomplete intermediate laboratory data, absence of bone marrow examination and repeat biopsy, and restricted observation window mean that causality between rheumatoid arthritis and the kidney disease, the possible presence of a small hematological clone, and rituximab’s efficacy all remain open questions. Nevertheless, the case delivers a durable diagnostic lesson: establishing a truly monotypic fibrillary glomerulonephritis demands the integration of routine immunofluorescence, IgG-subclass assessment, pronase-digested paraffin-embedded immunofluorescence, DNAJB9 immunohistochemistry, and electron microscopy. Light-chain restriction alone is never enough, and monotypic deposits warrant careful hematological evaluation, even when, as here, the hunt for a culprit clone comes up empty.

Subject of Research: Monotypic IgG1-lambda fibrillary glomerulonephritis associated with rheumatoid arthritis without monoclonal gammopathy

Article Title: Case Report: Monotypic IgG1-λ fibrillary glomerulonephritis associated with rheumatoid arthritis

Article References: Nedoroscik, A., Moravcova, J., Manakova, L., Zakiyanov, O., Rysava, R., Tesar, V., & Kollar, M. (2026). Case Report: Monotypic IgG1-λ fibrillary glomerulonephritis associated with rheumatoid arthritis. Frontiers in Nephrology, 6, Article 1932311. https://doi.org/10.3389/fneph.2026.1932311

Image Credits: AI Generated

DOI: 10.3389/fneph.2026.1932311

Keywords: fibrillary glomerulonephritis, rheumatoid arthritis, monotypic deposits, DNAJB9, kidney biopsy, rituximab, monoclonal gammopathy, nephrotic syndrome, light-chain restriction, immunofluorescence, electron microscopy, podocytes

Diabetic kidney disease is the leading cause of end-stage kidney disease worldwide, and even with modern therapies, many patients continue to progress toward dialysis. At the heart of the damage sit podocytes, specialized cells whose interlocking foot processes form the final barrier that stops proteins from leaking into the urine. When podocytes are injured and lost, proteinuria and glomerulosclerosis follow, and the process is largely irreversible. Two pathways have long been implicated: the toxic accumulation of the lipid ceramide in glomeruli, and the loss of calcium homeostasis that shatters the podocyte’s delicate cytoskeleton. What was missing was the physical link between the two, the precise molecular event that turns fat overload into a calcium catastrophe.

To find it, the team, led by Aiping Duan and Hao Bao of Jinling Hospital and Nanjing University, performed an integrated analysis of gene and protein expression data from diabetic glomeruli, drawing on public datasets including GSE142025, GSE236426 and GSE96804. Using elastic net regression, bootstrap resampling, cross-validation and permutation testing to separate genuine disease hubs from statistical noise, they ranked candidate genes and focused on Adipocyte Enhancer-Binding Protein 1, or Aebp1. Its expression rose steadily as kidney function declined, and immunofluorescence staining of human biopsy tissue confirmed that the protein accumulated prominently in injured podocytes, a pattern mirrored in a mouse model of diabetes induced by streptozotocin and a high-fat diet.

The researchers then asked whether Aebp1 was merely a bystander or an active culprit. Injecting an Aebp1-overexpressing adenovirus into the renal cortex of healthy mice was enough to trigger proteinuria, glomerulosclerosis and the characteristic flattening of podocyte foot processes seen under the electron microscope. Conversely, mice engineered to lack Aebp1 specifically in podocytes were substantially protected: after induction of diabetes, they showed less protein leakage, less scarring and better-preserved filtration architecture. The same protective effect appeared in a second model, adriamycin-induced nephropathy, suggesting that the pathway is not unique to diabetes but may operate across proteinuric kidney diseases, including focal segmental glomerulosclerosis.

The mechanistic trail began with lipidomics. When the team forced Aebp1 expression in cultured mouse podocytes, digital RNA sequencing showed more than three thousand genes changing, with the altered genes heavily enriched in cytoskeletal pathways. Untargeted lipidomics revealed 213 differentially abundant lipids, and among them ceramides and sphingomyelins topped the list. Treating podocytes with C16-ceramide alone reproduced the cytoskeletal collapse, while genetic knockout of Aebp1 in diabetic mice blunted ceramide accumulation in their podocytes. The lipid was not just a correlate; it was sufficient to cause the damage pattern.

How does Aebp1 raise ceramide in the first place? The answer ran through inflammation. Aebp1 overexpression degraded the inhibitory protein IkB-alpha and drove phosphorylated NF-kB p65 into the nucleus, and luciferase reporter assays confirmed that NF-kB binds directly to the promoter of Neu3, a gene encoding a sialidase enzyme central to the ceramide salvage pathway. Blocking NF-kB with the inhibitor BAY 11-7082 suppressed both the Neu3 surge and the ceramide buildup. The chain of command, from Aebp1 through NF-kB to Neu3 to ceramide, held up in diabetic mouse kidneys as well as in culture dishes.

The study’s boldest claim concerned what ceramide does next. Screening calcium channel genes, the researchers found that Trpc6 and Calhm2 both rose after ceramide treatment, but Calhm2, a channel previously studied in the brain and never implicated in kidney physiology, responded most dramatically. Overexpressing Calhm2 raised intracellular calcium and disrupted the cytoskeleton; silencing it blunted the response. Crucially, ceramide did more than increase the channel’s abundance. Within fifteen minutes, ceramide triggered a dose-dependent calcium surge in podocytes, amplified by Calhm2 overexpression and abolished by Calhm2 knockdown, indicating direct activation of the channel by the lipid.

Structural evidence sealed the argument. Molecular docking simulations using the cryo-EM structure of human Calhm2 predicted a hydrogen bond between ceramide and the glutamine residue at position 232 of the channel. Surface plasmon resonance then measured a binding affinity of 1.225 micromolar, a strength consistent with a genuine regulatory interaction. In effect, the researchers had caught a lipotoxic metabolite in the act of opening a gate: ceramide binds Calhm2, calcium floods in, and the podocyte’s actin scaffolding comes apart. This lipid-gated mechanism differs from the mechanical and receptor-mediated activation described for Trpc6 and Piezo1, broadening the framework of how calcium dysregulation injures the kidney filter.

The translational payoff came from urine. Analyzing samples from 55 patients with biopsy-proven diabetic kidney disease and 20 healthy controls, the team found that urinary Aebp1 mRNA levels clearly separated patients from controls, achieving an area under the receiver operating characteristic curve of 0.924, which held up under cross-validation at 0.850. More importantly, urinary Aebp1 correlated with 24-hour proteinuria and independently predicted the severity of glomerulosclerosis on biopsy: after adjusting for tubular fibrosis, age and gender, each unit increase in log-transformed expression corresponded to roughly a four-unit rise in the proportion of scarred glomeruli, explaining about 21 percent of the remaining variance.

The biomarker also looked forward. Over a follow-up extending to 55 months, patients with high baseline urinary Aebp1 faced a significantly higher cumulative incidence of the study’s renal endpoint, a 30 percent or greater decline in estimated glomerular filtration rate. Restricted mean survival time analysis showed high-expression patients losing about 7.4 months of event-free time over 42 months, and penalized multivariable logistic regression yielded an adjusted odds ratio of 4.31 for kidney function decline after accounting for baseline eGFR. The authors caution that the cohort is modest and that upstream triggers of Aebp1, the roles of other ceramide chain lengths, and definitive in vivo tests of Neu3 and Calhm2 remain open questions. But the core message is striking: a fat molecule, a previously obscure calcium channel, and a measurable urinary signal now form a single, testable pathway, one that repositions lipids as active signaling molecules and offers clinicians a noninvasive window into the health of the kidney’s most vulnerable cells.

Subject of Research: The role of Aebp1, ceramide and the Calhm2 calcium channel in podocyte injury in diabetic kidney disease

Article Title: Aebp1 drives a ceramide-gated Calhm2 calcium influx that injures podocytes in diabetic kidney disease

Article References: Duan, A., Jiang, Y., Wang, X., Chen, Z., Dong, P., Guo, Z., Qin, W., & Bao, H. (2026). Aebp1 drives a ceramide-gated Calhm2 calcium influx that injures podocytes in diabetic kidney disease. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.10.017

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.10.017

Keywords: diabetic kidney disease, podocytes, Aebp1, ceramide, Calhm2, calcium signaling, NF-kB, Neu3, glomerulosclerosis, urinary biomarker, lipotoxicity, focal segmental glomerulosclerosis

The cells at the center of the story are podocytes, highly specialized epithelial cells that wrap around the tiny capillary loops of the glomerulus, the kidney’s filtration unit. Podocytes extend intricate foot processes that interlock to form slits through which blood is filtered, and their integrity is essential for keeping protein from leaking into the urine. When podocytes are injured or lost, the filtration barrier breaks down, proteinuria develops, and progressive scarring follows. Podocyte injury is widely regarded as a decisive event in diabetic kidney disease, which is why understanding exactly how high blood sugar damages these cells has become one of the most pressing questions in nephrology.

The new research focuses on an unexpected player: FTO, the fat-mass and obesity-associated protein. FTO first rose to fame through genome-wide association studies linking variants in its gene to human obesity, but it was later shown to be an enzyme that removes a specific chemical modification from RNA molecules. That modification, N6-methyladenosine, or m6A, is the most abundant internal mark on messenger RNA in higher organisms. By adding or erasing m6A, cells can fine-tune how long a given mRNA survives, how efficiently it is translated into protein, and how it is processed. In earlier work, the team had manipulated FTO in podocytes and performed parallel methylated RNA immunoprecipitation sequencing and RNA sequencing, a combination that reveals both which transcripts carry m6A marks and how overall gene expression changes. That screen pointed them toward early growth response 1, or EGR1, a transcription factor whose precise role in diabetic kidney disease had remained unclear.

The findings that followed connect the dots in a strikingly mechanistic way. The researchers demonstrated that FTO is critical to podocyte injury because it enhances the stability of EGR1 mRNA in a manner dependent on m6A and on YTHDF2, a reader protein that binds methylated RNA and directs its fate. In other words, by removing methyl marks from the EGR1 transcript, FTO protects that message from YTHDF2-mediated degradation, allowing more EGR1 protein to be produced. The team also found that EGR1 is elevated in podocytes taken from people with diabetic kidney disease, and that its levels correlate with estimated glomerular filtration rate and with 24-hour urinary protein, two clinical measures of how well the kidney is functioning and how badly the filter is leaking.

Experiments in cultured human podocytes reinforced the picture. When the cells were exposed to high glucose, mimicking the diabetic environment, EGR1 expression climbed. Silencing EGR1 eased both the injury and the inflammation that high glucose provokes in podocytes, while forcing the cells to overproduce EGR1 made the damage worse. This dose-and-direction relationship, in which turning the gene down protects and turning it up harms, is exactly what one would expect from a genuine driver of the disease process rather than a passive bystander.

The mechanistic core of the study lies in what EGR1 does once it is produced. Using chromatin immunoprecipitation, the researchers showed that EGR1 binds directly to the promoter of STING1, the gene encoding stimulator of interferon genes 1, a protein better known as a central hub of innate immune signaling. By occupying its promoter, EGR1 boosts STING1 transcription, which in turn activates the STING1/TBK1/NF-κB signaling cascade. This cascade is a classic inflammatory pathway: STING1 activates TBK1, a kinase that then activates NF-κB, a transcription factor that switches on a battery of inflammatory genes. The result is a self-reinforcing inflammatory attack on the podocyte from within, driven ultimately by an RNA modification laid down by FTO.

To test whether the pathway matters in a living organism, the team turned to mouse models of diabetes induced by streptozotocin and a high-fat diet, which together reproduce key features of the human disease. Using adeno-associated virus vectors to deliver genetic constructs specifically to podocytes, they deleted or upregulated EGR1 in these cells. The outcome was unambiguous. Podocyte-specific deletion of EGR1 significantly reduced podocyte and glomerular damage in the diabetic mice, preserving the structure of the filtration barrier. Conversely, when EGR1 was deliberately elevated in podocytes, the mice suffered worse podocyte injury and heavier proteinuria. The same gene that protected cells when removed caused harm when amplified, confirming EGR1 as a pivotal node in the disease cascade in vivo.

The study is notable for the way it stitches together three layers of biology that are usually studied separately: epitranscriptomics, the chemistry of RNA modifications; transcriptional regulation, the control of gene expression by DNA-binding factors; and innate immunity, the inflammatory machinery that cells deploy against perceived threats. In the podocytes of a diabetic kidney, these layers converge into a single pathway. High glucose and FTO activity conspire to stabilize EGR1 mRNA, EGR1 protein then switches on STING1, and the STING1/TBK1/NF-κB axis ignites inflammation that erodes the kidney’s filter. Each link in that chain is a potential point of intervention, and the authors suggest that EGR1 itself could be a prospective new treatment strategy for diabetic kidney disease.

The clinical stakes are considerable. Current therapy for diabetic kidney disease rests on controlling blood glucose and blood pressure and on blocking the renin-angiotensin system with drugs such as angiotensin-converting enzyme inhibitors, alongside newer agents including SGLT2 inhibitors. Yet a large fraction of patients still progress toward dialysis or transplant, so molecular targets that address the injury process itself, rather than its systemic drivers, are eagerly sought. Because EGR1 sits downstream of FTO and upstream of the inflammatory cascade, drugging it or its partners might blunt podocyte inflammation even when metabolic control is imperfect. Any such approach would need to reckon with the fact that EGR1 is an immediate-early transcription factor with many roles in other tissues, so specificity will be a central challenge for future drug development.

There are also caveats that temper the excitement. The human evidence consists of correlations between EGR1 levels in podocytes and clinical markers, which, while consistent with the mechanistic data, cannot by themselves prove causation in patients. The mouse model, though well established, does not capture every feature of human diabetic nephropathy, and the viral vectors used to manipulate EGR1 in podocytes are research tools rather than therapeutic vehicles. The published version of the study is open access, allowing clinicians and researchers worldwide to scrutinize the data, and the work was approved by the relevant ethics committees at Shandong Provincial Hospital with informed consent from all participants. Even so, the study offers something the field has lacked: a complete, testable narrative linking an RNA demethylase, a methylated mRNA, an immune signaling hub, and the slow-motion catastrophe of the diabetic glomerulus. If that narrative holds up in further studies, the humble chemical tag on a strand of RNA may turn out to be one of diabetes’ most consequential accomplices, and shutting down its effects could help millions of people keep their kidneys working longer.

Subject of Research: FTO-mediated m6A modification of EGR1 mRNA and its role in podocyte injury and inflammation in diabetic kidney disease

Article Title: FTO-mediated m6A modification of EGR1 mRNA promotes podocyte injury and inflammation via STING1 in diabetic kidney disease

Article References: Hu, J., Liu, Y., Lang, Y., Liu, B., Fan, X., Yang, M., Shen, N., Zhang, D., Zhang, X., Chai, S., Zeng, Z., Shang, J., Wang, R., & Lv, Z. (2026). FTO-mediated m6A modification of EGR1 mRNA promotes podocyte injury and inflammation via STING1 in diabetic kidney disease. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06474-w

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06474-w

Keywords: diabetic kidney disease, podocytes, FTO, EGR1, STING1, m6A modification, RNA demethylase, YTHDF2, NF-kappaB, inflammation, proteinuria, nephrology

The study, published in BMC Biology, focuses on sepsis-associated acute kidney injury, or S-AKI, a condition that affects a large proportion of critically ill patients and carries a high risk of progression to chronic kidney disease. The researchers set out to test whether the cholinergic anti-inflammatory pathway, a neuroimmune circuit that dampens inflammation through the alpha-7 nicotinic acetylcholine receptor, could protect the glomerulus, the microscopic ball of capillaries where blood is filtered. What makes the finding remarkable is that this pathway had previously been studied almost exclusively in immune cells and kidney tubules, not in podocytes, the specialized epithelial cells whose interlocking foot processes form the final, finest sieve of the filtration barrier.

Podocytes are among the most architecturally sophisticated cells in the body. Their foot processes wrap around the glomerular capillaries and are bridged by a slit diaphragm, a zipper-like protein junction that contains molecules such as nephrin, podocin, ZO-1, and the actin-bundling protein synaptopodin. When these structures are damaged, as happens during systemic inflammation, the barrier becomes leaky and albumin escapes into the urine, a condition called albuminuria that is both a marker and a driver of further kidney damage. Preserving podocyte architecture during sepsis has therefore been a long-standing goal in nephrology research.

To test their hypothesis, the researchers used a mouse model of sepsis induced by lipopolysaccharide, or LPS, a component of bacterial cell walls that triggers a powerful inflammatory response. When mice were pretreated with GTS-21, a well-characterized agonist of the alpha-7 nicotinic acetylcholine receptor, the results were striking. Kidney function improved, albuminuria was significantly reduced, and transmission electron microscopy revealed that the podocytes’ foot processes retained their normal slender architecture instead of the flattened, fused effacement characteristic of injury. Levels of nephrin, podocin, synaptopodin, and podocalyxin, the molecular pillars of the filtration barrier, were all better maintained in the treated animals, and the organization of ZO-1, a tight-junction scaffolding protein, was partially restored in both glomerular and tubular compartments of the kidney.

A crucial question remained: was the drug acting indirectly, by calming immune cells elsewhere in the body, or was it protecting podocytes themselves? To answer this, the team first mapped where the Chrna7 gene, which encodes the alpha-7 receptor subunit, is expressed within the glomerulus. Using multiplex fluorescent in situ hybridization, they found that Chrna7 signals were broadly distributed across glomerular cells, with partial overlap with podocin, a definitive podocyte marker. They also confirmed that alpha-7 receptor expression could be detected in cultured podocytes, establishing that these cells are equipped to respond to cholinergic signaling directly.

The decisive experiment came with genetics. The researchers generated mice in which Chrna7 was deleted specifically in podocytes, leaving the receptor intact everywhere else. In these knockout animals, the protective effect of GTS-21 was substantially weakened. The drug’s ability to reduce albuminuria was blunted, the preservation of podocyte marker proteins was diminished, and the maintenance of glomerular ZO-1 organization was compromised. This loss-of-function evidence demonstrates that the receptor within podocytes themselves makes a substantial contribution to the glomerular protection conferred by alpha-7 activation, and it establishes podocytes as a direct cellular target of the cholinergic anti-inflammatory pathway.

The team then moved to cultured podocytes to dissect the cellular mechanism. When podocytes were challenged with LPS in vitro, pretreatment with GTS-21 preserved synaptopodin, the actin-associated protein essential for foot process structure, and improved the continuity of ZO-1 staining along cell junctions. Because podocyte injury during inflammation is driven largely by pro-inflammatory signaling cascades inside the cell, the researchers turned to transcriptomic analysis, sequencing the RNA of podocytes under different conditions. The data revealed that alpha-7 activation blunted a key inflammatory program: the NF-kappa-B pathway, a master regulator of the inflammatory response that, when activated, moves its p65 subunit into the nucleus to switch on dozens of inflammatory genes.

Time-course experiments made the suppression of NF-kappa-B signaling visible in real time. In control podocytes exposed to LPS, the p65 subunit rapidly translocated into the nucleus, became phosphorylated, and drove the expression of its target genes. In podocytes pretreated with the alpha-7 agonist, including experiments using a second agonist, PNU-282987, this nuclear translocation was reduced, phosphorylation was diminished, and the expression of downstream target genes fell. Independent quantitative PCR replication confirmed the RNA-sequencing results, strengthening the conclusion that the receptor acts as a brake on one of the central inflammatory circuits that damages podocytes during sepsis.

The implications of the work extend beyond sepsis. The cholinergic anti-inflammatory pathway has attracted intense interest as a therapeutic target for years, with vagus nerve stimulation and alpha-7 receptor agonists being explored for a range of inflammatory diseases. By showing that podocytes carry functional alpha-7 receptors and that activating them preserves the structural integrity of the glomerular filtration barrier, the study reframes the pathway as a multi-compartment strategy: it calms immune cells, protects tubules, and now demonstrably shields the glomerulus itself. For patients with sepsis-associated kidney injury, in whom albuminuria predicts worse outcomes and progression to chronic kidney disease, such a strategy could address both the inflammatory storm and the structural collapse of the kidney’s filter at the same time.

The authors, led by Aobing Yang, Chia-Hsien Wu, and Tsuyoshi Inoue, caution that the findings come from preclinical mouse and cell-culture models, and translating them into clinical practice will require further work, including studies in human tissue and trials of alpha-7 agonists in patients with sepsis. GTS-21, also known as DMXBA, has already been tested in human studies for cognitive disorders, which may ease the path toward repurposing. Still, the study offers a compelling proof of concept that the nervous system’s anti-inflammatory reflex reaches all the way down to the smallest structures of the kidney, and that a single receptor, engaged at the right moment, can hold together the biological sieve on which every one of us depends. As sepsis continues to claim hundreds of thousands of lives each year worldwide, protecting the kidney’s filtration barrier through the body’s own cholinergic circuitry may prove to be one of the most elegant tools yet discovered for that fight.

Subject of Research: Alpha-7 nicotinic acetylcholine receptor activation protects podocytes and glomerular barrier integrity in sepsis-associated acute kidney injury

Article Title: Alpha-7 nicotinic acetylcholine receptor activation preserves podocyte integrity during sepsis-associated kidney injury

Article References: Yang, A., Wu, C.-H., Shimoyama, K., Yamamoto, R., Umene, R., Nakamura, Y., Zhang, Y., & Inoue, T. (2026). Alpha-7 nicotinic acetylcholine receptor activation preserves podocyte integrity during sepsis-associated kidney injury. BMC Biology. https://doi.org/10.1186/s12915-026-02758-6

Image Credits: AI Generated

DOI: 10.1186/s12915-026-02758-6

Keywords: sepsis-associated acute kidney injury, podocytes, alpha-7 nicotinic acetylcholine receptor, GTS-21, cholinergic anti-inflammatory pathway, albuminuria, NF-kappa-B signaling, glomerulus, nephrin, ZO-1, synaptopodin, kidney injury

The kidney’s filtering units, the glomeruli, depend on a specialized layer of cells called podocytes. These cells wrap around the glomerular capillaries with interdigitating foot processes, forming slit diaphragms that act as the final, exquisitely selective barrier preventing albumin and other precious proteins from leaking into the urine. Podocytes are terminally differentiated epithelial cells; once damaged, they do not readily regenerate. One of the most consequential forms of podocyte injury is a process known as epithelial-to-mesenchymal transition, or EMT, in which these highly specialized epithelial cells lose their characteristic architecture and adhesion molecules and begin expressing mesenchymal markers such as N-cadherin, vimentin, and fibronectin. The transformed cells become motile, detach from the glomerular basement membrane, and contribute to the fibrotic scarring that progressively chokes off renal function. Prior work has implicated the TGF-beta signaling pathway, and its intracellular mediator SMAD3, as a central driver of this transition in the diabetic kidney.

The Harbin team began not in the laboratory but in the data. By integrating transcriptomic datasets from public repositories, they searched for RNA-binding proteins that were aberrantly expressed in diabetic kidney tissue, and PTBP3 emerged as a standout candidate. Polypyrimidine tract-binding protein 3 is a member of a family of proteins that bind specific sequence motifs in messenger RNA molecules, influencing their stability, translation, and alternative splicing. PTBP3 has attracted increasing attention in oncology research, where it has been shown to promote epithelial-to-mesenchymal transition and metastasis in lung adenocarcinoma, drive growth in colorectal and gastric cancers, and modulate immune escape in gallbladder cancer. Its role in kidney disease, however, had remained essentially unexplored, making the new findings a notable expansion of the protein’s known biological territory.

To confirm that the computational signal reflected real biology, the researchers turned to animal and cell models. In mice made diabetic by injection of streptozotocin, a compound that selectively destroys insulin-producing beta cells and reliably induces hyperglycemia, PTBP3 levels rose in kidney tissue. The same elevation appeared in podocytes grown in culture and exposed to high glucose concentrations, the standard in vitro model of diabetic cellular stress. These convergent observations, in vivo and in vitro, established that PTBP3 upregulation is a reproducible feature of the diabetic kidney environment rather than an artifact of any single experimental system, and positioned the protein as a plausible participant in disease pathogenesis.

The decisive experiment came next. The team knocked down PTBP3 in diabetic mice and monitored the classic functional readouts of kidney injury. The results were striking: 24-hour urinary protein excretion, a direct measure of the damaged filtration barrier, was significantly reduced in the knockdown animals. Serum creatinine and blood urea nitrogen, the two workhorse clinical markers of declining kidney clearance, were also substantially attenuated compared with diabetic controls. In other words, removing this single RNA-binding protein preserved measurable kidney function in the face of ongoing diabetes.

Histological analysis told a matching structural story. Under the microscope, the kidneys of diabetic mice typically show glomerular hypertrophy, expansion of the mesangial matrix that crowds the filtering tuft, and the deposition of collagen-rich fibrotic tissue. In the PTBP3 knockdown animals, all of these pathological features were ameliorated. Renal fibrosis was reduced, and the glomerular architecture was better preserved. The researchers further demonstrated that PTBP3 silencing inhibited the epithelial-to-mesenchymal transition of podocytes in the diabetic mice, an effect visible at the molecular level as restored expression of E-cadherin, the epithelial adhesion molecule that anchors podocytes in place, alongside reduced expression of the mesenchymal markers N-cadherin, vimentin, and fibronectin. Cultured podocytes subjected to high glucose showed the same pattern, reinforcing the consistency of the mechanism across model systems.

The mechanistic core of the paper lies in how PTBP3 exerts these effects, and here the authors provide a satisfying molecular explanation centered on SMAD3, the transcriptional mediator of TGF-beta signaling that has long been associated with fibrotic disease. Using dual-luciferase reporter assays and RNA immunoprecipitation, the team showed that PTBP3 physically interacts with the 3-prime untranslated region of SMAD3 messenger RNA. This interaction stabilizes the transcript, increasing the total amount of SMAD3 protein produced and, consequently, the levels of its phosphorylated, active form. In effect, PTBP3 acts as a post-transcriptional amplifier: by protecting SMAD3 mRNA from degradation, it boosts the signaling output of the TGF-beta pathway, which in turn drives podocytes toward the mesenchymal, fibrosis-promoting state. When PTBP3 is removed, SMAD3 expression falls, phosphorylation declines, and the EMT program loses its principal engine.

This finding places PTBP3 within a growing map of post-transcriptional regulation in diabetic kidney disease. The SMAD3 axis itself is well established: genetic deletion of Smad3 has previously been shown to prevent renal fibrosis and inflammation in models of type 2 diabetic nephropathy, and multiple microRNAs and circular RNAs have been described that modulate SMAD3 expression in mesangial cells and podocytes. What the new study adds is a specific RNA-binding protein that tunes the pathway at the level of mRNA stability, a layer of control that has been harder to drug than receptors or kinases but is increasingly recognized as a rich source of therapeutic targets. The parallel with cancer biology is also instructive, since PTBP3 has been repeatedly linked to TGF-beta-driven EMT in tumors, suggesting that the protein operates a conserved program of epithelial plasticity that the diabetic kidney co-opts for pathological remodeling.

The clinical implications, while still distant, are worth considering carefully. Diabetic nephropathy affects an enormous fraction of the growing global population with diabetes, and a substantial share of patients progress to dialysis or transplantation despite current best care. A target that acts upstream of SMAD3, and that demonstrably reduces proteinuria and preserves histology in a diabetic mouse model, represents the kind of mechanistic entry point that could eventually yield new drug classes, whether antisense oligonucleotides, small molecules that disrupt the PTBP3-SMAD3 mRNA interaction, or delivery strategies aimed specifically at podocytes. The authors note that PTBP3 knockdown ameliorated renal fibrosis and preserved renal function, underscoring the therapeutic potential of targeting podocyte epithelial-mesenchymal transition in diabetic nephropathy. At the same time, the usual caveats apply: mouse models of streptozotocin-induced diabetes capture only part of human diabetic kidney disease, and PTBP3’s roles in other tissues, including its documented effects in hematopoietic and endothelial biology, will need to be weighed against any systemic intervention.

For now, the study stands as a clear demonstration that the fate of the kidney’s filtration barrier can be steered by a single post-transcriptional regulator. By tracing a line from public transcriptomic data through diabetic mice and glucose-stressed podocytes down to a specific interaction between an RNA-binding protein and the untranslated region of a fibrotic transcription factor, the Harbin researchers have connected a molecular mechanism to clinically meaningful outcomes: less protein in the urine, lower creatinine, less scarring, better-preserved glomeruli. If those findings can be replicated in additional models and extended toward human tissue validation, PTBP3 may join the short list of molecules that clinicians watch as potential handles on one of diabetes’ most feared complications. The work was supported by the Basic Scientific Research Business Expenses Project of Colleges and Universities in Heilongjiang Province, and all animal experiments were approved by the Ethics Committee of the First Affiliated Hospital of Harbin Medical University.

Subject of Research: The role of the RNA-binding protein PTBP3 in Smad3-dependent podocyte injury and fibrosis in diabetic nephropathy

Article Title: PTBP3 promotes diabetic nephropathy via Smad3-dependent podocyte-mesenchymal transition

Article References: Li, Y., Fu, Y., Wang, X., Ma, X., Cong, G., & Sui, M. (2026). PTBP3 promotes diabetic nephropathy via Smad3-dependent podocyte-mesenchymal transition. Molecular Biology Reports, 53(1), Article 1628. https://doi.org/10.1007/s11033-026-12788-6

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12788-6

Keywords: diabetic nephropathy, PTBP3, podocytes, SMAD3, epithelial-mesenchymal transition, renal fibrosis, RNA-binding proteins, TGF-beta signaling, chronic kidney disease, proteinuria, mRNA stability, kidney disease

The research team, led by Taiji Matsusaka of Tokai University School of Medicine, built a transgenic mouse platform designed to force podocytes back into the cell cycle on demand. The system exploits the Tet-On inducible expression technology, in which a tetracycline-responsive element drives transgene expression only when the antibiotic doxycycline is present. The authors microinjected a construct containing the Simian virus 40 large T antigen (SV40T) coding sequence, together with a lacZ reporter, into fertilized mouse eggs and established transgenic lines. SV40T is a viral oncoprotein best known for promoting cell-cycle entry by binding and functionally inactivating two key tumor suppressors, p53 and the retinoblastoma protein (Rb). Because it can push otherwise quiescent cells past the G1 restriction point, it is a standard tool for immortalizing podocytes in culture, making it a logical choice for attempts to stimulate division in vivo.

The transgenic line was crossed with Nphs2-rtTA mice, in which the reverse tetracycline transactivator is expressed specifically in podocytes under the podocin promoter. In double-transgenic offspring, doxycycline in the drinking water therefore triggered SV40T production exclusively in podocytes. The specificity was confirmed by immunostaining: after four to fourteen days of treatment, roughly twenty to thirty percent of podocytes per glomerular section expressed the viral antigen, while untreated animals and single-transgenic controls showed nothing. Critically, the forced cells did more than merely turn on the transgene. Between 9.3 and 17.7 percent of podocytes became positive for Ki67, a marker spanning late G1 through mitosis, incorporated bromodeoxyuridine to indicate DNA synthesis, expressed Aurora kinase B, and occasionally displayed mitotic figures. At the same time, p57Kip2, a cyclin-dependent kinase inhibitor that typifies the mature podocyte state, was downregulated in the SV40T-positive cells. The quiescent filter cells had, by every molecular criterion, re-entered the cell cycle.

In adult mice, however, this proliferative push came at a steep price. Cytokinesis frequently failed, leaving podocytes multinucleated or bearing enlarged nuclei. Within the first week of doxycycline exposure, kidney morphology was largely preserved apart from microvillous transformation of the podocytes, but the urinary albumin-to-creatinine ratio climbed dramatically, from control values near 0.02 to 15.76 by day seven and 40.27 by day fourteen. By two weeks, the slit diaphragm proteins nephrin and podocin were reduced and the injury marker desmin appeared in glomerular segments. After four or more weeks of continuous induction, every treated mouse developed focal segmental glomerulosclerosis of the usual type, complete with secondary tubulointerstitial damage in the most severely affected kidneys. Intriguingly, the damaged podocytes no longer expressed SV40T, apparently because podocyte injury extinguishes Nphs2-driven rtTA expression, an automatic brake on the system. Repeated short treatment cycles combined with the angiotensin receptor blocker losartan produced only a modest, marginal increase in podocyte counts, confirming that adult podocytes resist expansion even under carefully titrated conditions.

That failure redirected the strategy toward embryogenesis, a period when podocyte progenitors are naturally proliferative and the glomerulus has not yet been exposed to high filtration pressures. Pregnant dams carrying SV40T/rtTA embryos received doxycycline from embryonic day 14.5 until birth. The team also incorporated a third genetic element: Bcl2 knockout alleles. Homozygous Bcl2-deficient mice are a classical model of oligomeganephronia, a condition in which apoptosis of undifferentiated mesenchymal cells between embryonic days 13 and 16 drastically reduces nephron number, forcing the surviving glomeruli to enlarge compensatorily. This provided a natural test bed for whether extra podocytes could augment, or even drive, glomerular hypertrophy under strong physiological pressure.

The results at birth were striking. Newborn double-transgenic pups, on either Bcl2 background, carried markedly more podocytes than their littermate controls, with nearly all inner-cortical podocytes expressing SV40T and most of those positive for Ki67. On average, the number of WT1-positive podocytes per glomerulus rose by 54 percent. Importantly, these surplus cells had not simply dedifferentiated into a pathological mass: they retained robust expression of podocin, WT1, and podocalyxin, the molecular signature of committed podocytes, and they did not resemble the crescents seen in collapsing glomerulopathies. Yet the glomerular tuft area, measured by painstaking morphometry of all non-tangential glomeruli across entire kidney cross-sections, was not significantly larger than in controls. Even individual glomeruli loaded with excessive podocytes never exceeded the size of ordinary control glomeruli. The correlation between podocyte number and glomerular volume, so reliable in normal growth, had been decisively broken from the other direction.

Rather than integrating neatly into the filtration barrier, the extra podocytes misbehaved structurally. They formed multilayers instead of the normal monolayer, detached from the glomerular basement membrane, and scattered into Bowman’s space or even into tubular lumens. Double immunostaining showed that most cells remained mononuclear, with WT1-positive nuclei enclosed by podocalyxin, arguing against rampant failed division. Markers of DNA damage (gammaH2AX) and apoptosis (cleaved lamin A) appeared in only a small fraction of cells, averaging 0.26 and 0.39 per glomerulus respectively. The authors interpret this pattern as evidence that adhesive failure during mitotic rounding, rather than programmed cell death, is the dominant mechanism of loss. During mitosis, epithelial cells normally round up and transiently weaken integrin-mediated adhesion before reattaching; podocytes, with their intricate foot-process architecture and dependence on precise attachment to the basement membrane, appear exceptionally vulnerable to this structural upheaval.

The Bcl2-deficient experiments sharpened the conclusion. All Bcl2 knockout mice, regardless of transgene status, showed severe renal hypoplasia with few, enlarged glomeruli. In SV40T-expressing Bcl2-deficient pups, podocyte numbers rose as in the wild-type background, but many cells again detached from the glomerular basement membrane, and the tuft area was actually significantly smaller than in Bcl2-deficient littermates lacking the transgene. In other words, even when compensatory hypertrophy should have been pushing glomeruli to expand, the surplus, poorly anchored podocytes appeared to exert a squeezing effect that constrained tuft growth. Structural integration, not cell supply, proved to be the limiting factor.

Postnatal follow-up sealed the outcome. Among 26 pups analyzed at postnatal day 7, the previously excessive podocyte populations had vanished: podocyte number and tuft area in transgenic animals were indistinguishable from controls, and glomeruli containing more than thirty podocytes, common at birth, were no longer observed. The authors propose several non-exclusive explanations for this elimination. Podocytes may lack the stringent planar-division orientation control that keeps renal tubular epithelia in a monolayer, dooming misplaced daughters. Alternatively, a quality-control mechanism known as cell competition, in which fitter neighbors actively expunge less fit cells, may recognize SV40T-induced podocytes as losers and remove them, effectively imposing an occupancy-management system on the glomerular tuft.

The broader implication is a reframing of how glomerular size is set. Because the Nphs2 promoter only activates once podocytes have passed the S-shaped body stage, the study could not boost progenitor pools at earlier stages, and the authors conclude that glomerular size is likely determined at or before that point in nephrogenesis. Adding podocytes afterward, even during the permissive embryonic environment, cannot override the architectural constraints of the developing tuft. For regenerative medicine, the message is sobering but precise: future strategies to expand the podocyte population must either target earlier progenitor stages or solve the biophysical problems of division orientation and cell-matrix adhesion so that new cells can stably integrate into the filter. Simply forcing mature or nearly mature podocytes to cycle, whether by viral oncoproteins or other means, produces cells that the glomerulus cannot accommodate and ultimately discards.

Subject of Research: The effect of experimentally induced podocyte proliferation on glomerular size in mice

Article Title: Increase in podocyte number induced by SV40T antigen during the fetal stage does not expand glomerular size in mice

Article References: Matsusaka, T., Ichimura, K., Miyaki, T., & Koizumi, M. (2026). Increase in podocyte number induced by SV40T antigen during the fetal stage does not expand glomerular size in mice. Physiological Reports, 14(19), Article e71114. https://doi.org/10.14814/phy2.71114

Image Credits: AI Generated

DOI: 10.14814/phy2.71114

Keywords: podocytes, glomerulus, SV40 large T antigen, kidney development, Tet-On system, focal segmental glomerulosclerosis, Bcl2 deficiency, oligomeganephronia, mitotic catastrophe, cell competition, glomerular basement membrane, chronic kidney disease

Minimal change disease is defined by an abrupt onset of heavy proteinuria, low blood albumin, and elevated blood lipids. Under the electron microscope, the hallmark is the diffuse effacement of podocyte foot processes, the interdigitating projections that anchor these cells to the glomerular basement membrane and dynamically regulate filtration permeability. Yet light microscopy typically reveals an unremarkable glomerular architecture, and renal biopsies from many patients show no significant infiltration of T cells. This paradox has haunted nephrologists for decades: aberrant T cell activation is clearly implicated in driving podocyte injury, but the mechanism by which T cells are mobilized without ever visibly entering the kidney has remained elusive. Compounding the clinical problem, roughly twenty to thirty percent of adult patients develop steroid dependence or resistance, and some progress to end-stage renal disease.

The research team, led by investigators at Nanjing University Medical School and collaborating institutions, approached the problem by integrating clinical analysis with in vitro and in vivo experimental models. Their central hypothesis centered on extracellular vesicles—lipid bilayer-enclosed nanoscale particles that shuttle proteins, lipids, nucleic acids, and metabolites between cells. Exosomes, the smallest of these vesicles at thirty to one hundred fifty nanometers, have previously been found at elevated levels in the urine of patients with metabolic syndrome-associated kidney disease, renovascular hypertension, and preeclampsia, with their abundance correlating with proteinuria severity. What remained undefined was whether podocyte-derived exosomes could actually mediate communication between podocytes and T cells through antigen presentation.

In laboratory experiments, the researchers cultured mouse podocytes with a model antigen and interferon-gamma, an inflammatory cytokine. When naive T cells from OT-I transgenic mice—whose receptors specifically recognize the model antigen—were co-cultured with these activated podocytes, flow cytometry revealed a striking upregulation of the activation markers CD69 and CD25. Critically, adding GW4869, an inhibitor of exosome secretion, abolished this activation, indicating that the podocytes were stimulating T cells through released exosomes rather than direct contact. Characterization of the isolated vesicles confirmed their exosomal identity: they carried the canonical markers TSG101, ALIX, and CD63 but lacked the negative control protein calnexin, displayed a characteristic cup-shaped morphology under transmission electron microscopy, and measured fifty to one hundred fifty nanometers in diameter.

The mechanistic crux of the study lies in major histocompatibility complex class I molecules. Interferon-gamma stimulation significantly increased the expression of MHC-I, MHC-II, and the costimulatory molecules CD80 and CD86 on podocyte-derived exosomes. When the researchers generated podocytes deficient in MHC-I through lentiviral knockdown, exosomes from these cells completely failed to activate T cells. In vivo, the team depleted professional antigen-presenting cells by whole-body irradiation and then injected MHC-I-deficient exosomes alongside OT-I CD8-positive T cells into mice with puromycin aminonucleoside-induced minimal change disease. These mice exhibited significantly lower urinary protein-to-creatinine ratios and markedly fewer activated interferon-gamma-positive T cells in renal lymph nodes and spleen compared with controls receiving intact exosomes. The conclusion was unambiguous: CD8-positive T cell activation by podocyte exosomes is strictly dependent on MHC-I-mediated antigen presentation.

Perhaps the most elegant finding concerns the division of labor between podocyte exosomes and dendritic cells. While exosomes alone could trigger T cell activation, they could not drive T cell proliferation without dendritic cells present. In irradiated mice lacking dendritic cells, podocyte exosomes still activated kidney-resident memory T cells and worsened proteinuria, but systemic T cell expansion was blunted. When the researchers reconstituted dendritic cells by bone marrow-derived cell transfer, the full pathological cascade returned. This suggests a biphasic mechanism the authors describe as local activation followed by systemic amplification: exosomes mediate antigen presentation to tissue-resident memory T cells within the kidney to ignite early inflammation, while dendritic cells relay antigenic signals to secondary lymphoid organs, where they recruit and expand effector T cell populations. The data favor a reprocessing model in which dendritic cells internalize exosomes, degrade their cargo, and load peptides onto their own MHC-I molecules, rather than simply acquiring pre-formed complexes on their surface.

To establish clinical relevance, the team developed an autologous pairing system using samples from twenty patients with biopsy-confirmed minimal change disease and twenty with lupus nephritis. Plasma from each patient was split so that podocyte-derived exosomes, identified by the podocyte marker podocalyxin, could be isolated and paired with naive CD8-positive T cells from the same individual’s blood. Exosomes from both patient groups carried high levels of MHC-I, MHC-II, CD80, and CD86. Exposure to these autologous exosomes triggered robust T cell receptor signaling, evidenced by increased phosphorylation of ZAP-70 and Lck, followed by CD69 and CD25 upregulation, substantial proliferation by seventy-two hours, and elevated interferon-gamma secretion. Mass spectrometry of patient-derived exosomes identified 108 proteins unique to minimal change disease samples, including immunoglobulin variable region components and complement proteins, and bioinformatic screening against the Immune Epitope Database flagged twelve candidate autoantigens, with dermcidin prioritized on the basis of an HSP70-binding domain and an embedded HLA-A*03 epitope. Levels of exosomal MHC-I and CD80 correlated strongly with disease severity measures.

The therapeutic implications were tested through two complementary strategies. Pharmacological inhibition with GW4869 reduced renal exosome burden, lowered the urinary albumin-to-creatinine ratio, and decreased effector CD8-positive interferon-gamma-positive T cells in renal lymph nodes and spleen. More precisely, the team engineered podocyte-specific manipulation of Rab27a, a membrane-binding GTPase that governs the docking of multivesicular endosomes with the plasma membrane and thereby controls exosome release. Genetic overexpression of Rab27a in podocytes accelerated disease, while podocyte-specific knockout suppressed exosome secretion even more effectively than GW4869 and attenuated disease progression. Because GW4869 lacks tissue specificity and could disrupt beneficial exosome secretion in immune and endothelial cells, the podocyte-restricted genetic approach provides a cleaner proof of principle, pointing toward kidney-targeted nanocarrier delivery systems or CRISPR-based spatiotemporal control of Rab27a as future therapeutic avenues.

The study’s authors acknowledge that the candidate autoantigens remain at the level of computational prediction and will require direct validation through MHC-I immunopeptidomics and autologous T cell priming assays. Mouse models also cannot fully recapitulate human disease, and questions remain about whether exosomes influence B cells and macrophages as well. Nevertheless, the work fundamentally redefines podocytes as non-classical antigen-presenting cells and identifies a concrete, targetable pathway—Rab27a-dependent exosome release—linking podocyte injury to systemic T cell immunity. For a disease in which twenty to thirty percent of adult patients fail first-line steroid therapy, the prospect of intercepting these molecular messengers before they mobilize the immune system represents a compelling new frontier in precision nephrology.

Subject of Research: Podocyte-derived exosome-mediated antigen presentation and CD8-positive T cell activation in minimal change disease

Article Title: Podocyte-derived exosomes instruct dendritic cell-dependent CD8 + T cell activation and proliferation in renal inflammation

Article References: Qian, B., Mao, S., Chen, Y., Liu, Y., Zhang, M., Zhu, D., Zen, K., Wang, Y., Liu, Z., & Li, L. (2026). Podocyte-derived exosomes instruct dendritic cell-dependent CD8+ T cell activation and proliferation in renal inflammation. Journal of Advanced Research, 88, 885-898. https://doi.org/10.1016/j.jare.2026.01.032

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.01.032

Keywords: podocytes, exosomes, minimal change disease, CD8 T cells, MHC-I, dendritic cells, Rab27a, nephrotic syndrome, antigen presentation, renal inflammation, extracellular vesicles, proteinuria

Lmx1b is a LIM homeodomain transcription factor with a well-established role in development, and nowhere is that role more consequential than in the podocytes, the specialized epithelial cells that wrap around the capillaries of the glomerulus. Podocytes form the last and most selective layer of the glomerular filtration barrier, interdigitating with one another through foot processes that are bridged by a slit diaphragm — a molecular zipper that prevents proteins such as albumin from escaping into the urine. When Lmx1b function is compromised, as it is in humans with nail-patella syndrome who develop nephropathy, podocytes fail to express a normal complement of slit diaphragm and basement membrane components, and the filtration barrier leaks. Proteinuria follows, and with it a progressive scarring process that can end in focal segmental glomerulosclerosis and kidney failure.

The researchers behind the new study set out to understand precisely how a dysfunctional LIM domain destabilizes the podocyte, and whether the cell’s own protein quality control systems are part of the problem or part of the solution. Using knock-in mice in which the LIM domains of Lmx1b carry point mutations that impair their zinc-coordinating structure, the team showed that the mutant protein is not simply inert. Instead, it appears to engage the same genomic targets as the wild-type factor while failing to execute the transcriptional program properly, producing a population of podocytes that are chronically stressed, structurally disorganized, and progressively unable to maintain their elaborate cytoarchitecture. The animals develop robust albuminuria early in life, and their glomeruli show the foot process effacement and segmental scarring characteristic of human FSGS.

What happens to protein homeostasis — proteostasis — inside such a stressed podocyte is where the story takes an unexpected turn. The authors found that the mutant Lmx1b protein itself is recognized by cellular quality control machinery and shuttled to the proteasome for destruction. In trying to clear the defective transcription factor, podocytes appear to ramp up proteasomal activity and, in doing so, deplete their degradative capacity for other client proteins. The result is a kind of proteolytic bottleneck: essential regulatory proteins and structural components that depend on tightly calibrated turnover are degraded too aggressively or incompletely, and the podocyte’s already fragile cytoskeleton and slit diaphragm lose what little stability they have left. Proteostasis, in this model, is not merely a bystander to disease but an active participant in its progression.

That mechanistic picture immediately suggested a therapeutic experiment. If excessive proteasomal degradation is accelerating podocyte collapse, then temporarily inhibiting the proteasome might relieve the pressure. The team treated the knock-in mice with established proteasome inhibitors and monitored proteinuria, glomerular histology, and the molecular state of the podocytes over time. The results were striking. Treated animals showed a marked reduction in albumin excretion compared with vehicle-treated controls, and their glomeruli retained more of the normal foot process architecture. At the molecular level, the intervention rebalanced the podocyte proteome, preserving proteins that had been prematurely depleted in untreated mutants and dampening the stress responses that accompany uncontrolled protein turnover.

The authors are careful to frame the effect as modulation rather than rescue. Proteasome inhibition does not repair the mutant Lmx1b protein, restore its DNA binding specificity, or rewrite the developmental errors that caused the disease. What it does is buy time. By slowing the degradation of proteins the podocyte still produces correctly, the treatment allows the cell to maintain a functional filtration barrier despite an upstream genetic defect that cannot be corrected. In a disease landscape where most genetic kidney disorders have no targeted therapy at all, the demonstration that a downstream, druggable node in the cellular network can meaningfully change the disease trajectory is significant.

Proteasome inhibitors are not a new class. Bortezomib and related agents are approved therapies for multiple myeloma, where they exploit the fact that malignant plasma cells, which churn out enormous quantities of immunoglobulin, are exquisitely dependent on proteasomal degradation to survive. Their safety profile in the kidney has been scrutinized because the drugs can, paradoxically, cause proteinuric injury in some patients through direct tubular toxicity. The new study therefore does not imply that proteasome inhibitors are ready for immediate use in patients with Lmx1b-related nephropathy. Dose, timing, duration, and the specific compound all matter enormously, and the therapeutic window that exists in a mouse may be narrow or absent in a human. What the work establishes is a mechanism and a proof of principle: that proteostasis manipulation can change the course of a structural kidney disease driven by a transcription factor mutation.

The broader implications reach beyond Lmx1b. A growing list of inherited and acquired glomerular diseases — including those driven by mutations in podocyte genes such as NPHS1, NPHS2, TRPC6, and components of the cytoskeleton — involve downstream consequences that are not the mutated protein itself but the misregulation of protein turnover, ER stress, and proteasomal load. If the bottleneck mechanism identified here proves generalizable, proteostasis-targeting strategies could become a shared therapeutic axis for a family of disorders that currently have few options beyond supportive care and, eventually, dialysis or transplantation. The podocyte, once considered a terminally differentiated cell with limited capacity for self-repair, is increasingly understood as a dynamic system whose fate can be influenced by manipulating quality control pathways.

Several questions will need answers before the approach moves toward the clinic. The study’s follow-up period, while sufficient to demonstrate reduced proteinuria, does not establish whether long-term proteasome modulation slows the progression to glomerulosclerosis or preserves kidney function over the lifespan of the animals. It also remains to be seen whether the benefit depends on catching the disease early, before irreversible scarring has begun, or whether established lesions also respond. And because proteasome activity is essential in virtually every tissue, any chronic regimen will have to navigate a delicate balance between protecting the podocyte and harming other organs. Nonetheless, the fact that a single course of treatment produced measurable improvement in proteinuria — a clinical endpoint that correlates strongly with long-term renal outcomes in human glomerular disease — gives the finding real translational weight.

For the researchers, clinicians, and patients following the genetics of nephropathy, the study reframes what a LIM domain mutation actually does to the kidney. The damage is not a simple absence of a transcription factor; it is a cascade in which a defective protein disrupts gene expression, destabilizes the cell, and then drags the entire proteostasis network into a self-defeating overdrive. Interrupting that final stage of the cascade, with a drug class that already exists, turns a developmental catastrophe into a partially manageable physiological problem. It is a reminder that in complex genetic diseases, the most actionable therapeutic target is often not the broken gene itself, but the cellular systems that fail in its shadow — and that sometimes, the counterintuitive intervention of slowing down the cell’s own cleanup machinery is exactly what a stressed tissue needs to keep functioning.

Subject of Research: Proteasome inhibition as a therapy for proteinuria in mice with dysfunctional Lmx1b LIM domains

Article Title: Proteasome inhibition alleviates proteinuria in Lmx1b knock-in mice with dysfunctional LIM domains

Article References: Hermens, J., Lucke, L., Pieles, O., Maier, O., Othmen, H., Burghardt, T., Schmidt, A., Moser, M., Madej, M. G., Schwartz, U., Zaparty, M., & Witzgall, R. (2026). Proteasome inhibition alleviates proteinuria in Lmx1b knock-in mice with dysfunctional LIM domains. Nature Communications, 17(1), Article 9731. https://doi.org/10.1038/s41467-026-77485-1

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77485-1

Keywords: proteasome inhibition, proteinuria, Lmx1b, LIM domains, glomerulus, podocytes, focal segmental glomerulosclerosis, kidney disease, proteostasis, knock-in mice, genetic kidney disease, renal filtration barrier